Haleon Plc, the consumer health business spun out of GSK Plc last year, is exploring a divestiture of its ChapStick lip balm brand, according to people with knowledge of the matter.
(Bloomberg) — Haleon Plc, the consumer health business spun out of GSK Plc last year, is exploring a divestiture of its ChapStick lip balm brand, according to people with knowledge of the matter.
The company is working with advisers on a potential sale of the business that could fetch about $600 million, the people said, asking not to be identified discussing private information. Deliberations are at an early stage and the scope of the divestiture could change, they said.
A representative for Haleon declined to comment.
Haleon separated from the pharmaceutical giant in July. Its shares have risen 6% since then, giving it a market value of 30 billion pounds ($36 billion).
GSK still owns about 13% of Haleon’s shares, though Pfizer Inc. with a 32% stake is the company’s largest shareholder, according to data compiled by Bloomberg.
Haleon owns brands such as Centrum, Emergen-C, Tums and Advil. It’s also in the early stages of studying large potential deals to bulk up its brand portfolio, which might include combining with Sanofi’s $30 billion consumer-health operations, Bloomberg News reported in January.
–With assistance from Aaron Kirchfeld.
More stories like this are available on bloomberg.com
©2023 Bloomberg L.P.